Markets

Insider Trading

Hedge Funds

Retirement

Opinion

5 Oversold Stocks to Buy with Double-Digit ROE Growth

In this article, we will list the 5 Oversold Stocks to Buy With Double-Digit ROE Growth. Please visit 7 Oversold Stocks to Buy With Double-Digit ROE Growth if you’d like to see an extended list and the methodology behind it.

5. Insulet Corp. (NASDAQ:PODD)

Insulet Corp. (NASDAQ:PODD) is one of the 7 oversold stocks to buy with double-digit ROE growth.

On April 6, Evercore ISI reduced the price target on Insulet Corp. (NASDAQ:PODD) from $340 to $240, while maintaining an Outperform rating on the stock. Despite the downward revision to the target price, the stock still offers an adjusted upside of over 21% at the prevailing level.

Image by MayoFi from Pixabay

The adjustment is part of the firm’s broader revisions across medical technologies and life science tools segments, in line with the first-quarter earnings preview.

Back on March 13, Insulet Corp. (NASDAQ:PODD) announced a voluntary medical device correction for specific Omnipod 5 batches distributed within the United States. This crucial safety measure comes on the back of a manufacturing flaw that involved ripped internal insulin delivery tubing. This structural damage causes the drug to leak internally rather than enter the body properly. It significantly increases the risk of fatal diabetic ketoacidosis and extremely high blood glucose levels.

The company confirmed 18 serious adverse events resulting in hospitalization, none of which were fatal. Additionally, the company has explained that this particular anomaly, which affects about 1.5% of yearly global production, has no effect whatsoever on continuous glucose monitoring devices. To ensure that new patients start and uninterrupted customer shipments continue to be fully supported at the current level, management successfully adjusted quality control processes to prevent repeat incidents.

Insulet Corp. (NASDAQ:PODD) focuses on manufacturing and selling insulin management systems through the Omnipod platform. It offers a disposable tubeless pump called Omnipod Insulin Management System, whose design is specific to insulin-dependent diabetes. The company’s strategy revolves around high-volume automated manufacturing in the US and Malaysia, and contract manufacturing in China.

4. Tencent Music Entertainment Group (NYSE:TME)

Tencent Music Entertainment Group (NYSE:TME) is one of the 7 oversold stocks to buy with double-digit ROE growth.

On March 19, Barclays reduced the price target on Tencent Music Entertainment Group (NYSE:TME) from $28 to $20, which still yields a lucrative upside potential of more than 113% at the current level. The firm also maintained an Overweight rating on the stock.

Barclays pointed out that there is now more intense competition because of the presence of artificial intelligence-produced content availability on competing platforms. The firm expects the company to be on the defensive during fiscal 2026 amid such growing competition.

On March 18, Fawne Jiang from Benchmark downgraded the rating from Buy to Hold on Tencent Music Entertainment Group (NYSE:TME), while no change was made to the price target. Despite solid fourth-quarter financial results, the stock rating has been downgraded due to an increasingly uncertain outlook for fiscal year 2026.

Jiang noted that growing industry competitiveness will have a major impact on the growth of subscriptions overall. Furthermore, new structural issues are brought about by the quick changes in consumer consumption and content development brought about by artificial intelligence.

Tencent Music Entertainment Group (NYSE:TME) is an entertainment provider that offers online music, streaming, and virtual karaoke services. The company runs online music platforms that allow members to discover and share music, talk shows, audiobooks, podcasts, and other audio content.

3. Pony AI Inc. (NASDAQ:PONY)

Pony AI Inc. (NASDAQ:PONY) is one of the 7 oversold stocks to buy with double-digit ROE growth.

On April 8, Pony AI Inc. (NASDAQ:PONY) revealed that their robotaxi services in collaboration with Verne and Uber Technologies Inc. (NYSE:UBER) had kicked off commercially in Zagreb, Croatia. It represents the first commercial operation in Europe involving robotaxis, and customers can book and make payments for these services using the Verne app.

It is also possible to book these rides through the Uber app. The current operational coverage is approximately 90 square kilometers within important parts of Croatia’s capital, such as Zagreb Airport, and will soon extend across the whole city.

Earlier on April 7, Pony AI Inc. (NASDAQ:PONY) revealed that the company’s autonomous mobility solution, which was run with the cooperation of ComfortDelGro in Singapore, got the green light to start by-invite rides, marking the beginning of the final stage before opening to public usage.

The development marks progress in the company’s dual-engine growth model, which entails expanding the autonomous mobility solution in China as well as in other countries. The 12-kilometer-long route is operational in northeast Punggol and connects the residents of Punggol Northshore and Waterway Sunrise to facilities such as Oasis Terraces, Punggol Plaza, One Punggol, and Punggol Coast Mall while giving them access to the Punggol Coast MRT station and bus interchange.

Pony AI Inc. (NASDAQ:PONY) is involved in the autonomous mobility sector. It provides several services for AV, which include software deployment, vehicle engineering, and more. It also offers logistics platforms with transportation services, along with licensing and applications business that includes personally owned vehicle intelligent solutions, data analytics tools, and more.

2. Doximity Inc. (NYSE:DOCS)

Doximity Inc. (NYSE:DOCS) is one of the 7 oversold stocks to buy with double-digit ROE growth.

On April 8, Elizabeth Anderson from Evercore ISI downgraded Doximity Inc. (NYSE:DOCS) to In Line from Outperform with a price target from $30 to $25. The reasons for the downgrade, as highlighted by the analyst, included lower-than-expected forecasted growth in the market for 2026, competitive risk, and a fair valuation.

Anderson further stated that there has been low organic growth in the high single digits in Doximity’s fiscal year 2026 due to a decline in pharmaceutical advertising, which has not kept pace with R&D spend.

On March 17, Doximity Inc. (NYSE:DOCS) issued a detailed report examining how medical professionals throughout the United States are integrating AI into clinical practice. This report is the result of extensive research conducted between March 2025 and January 2026 with 3151 physicians from 15 different specialties.

According to the research, 94% of physicians either use these cutting-edge solutions now or are strongly inclined towards using them. Furthermore, 71% of practitioners stated that their primary operational concerns were accuracy and reliability. According to management, in order to successfully reduce administrative expenses, improve employee satisfaction, and increase direct patient care time at the existing level, strong physician engagement and transparent development are required.

Doximity Inc. (NYSE:DOCS) is a digital platform offering online networking services to healthcare and medical professionals. The company has an extensive network currently covering around 80% of U.S.-based physicians. Their AI-powered application helps in efficient HIPAA-compliant communication among healthcare professionals.

1. Compass Inc. (NYSE:COMP)

Compass Inc. (NYSE:COMP) is one of the 7 oversold stocks to buy with double-digit ROE growth.

On April 8, Matthew Bouley from Barclays reduced the price target on Compass Inc. (NYSE:COMP) from $15 to $12 while maintaining the Overweight rating. This downward revision came after the first quarter earnings preview that included target adjustments across the homebuilding and building goods industry.

The analyst believes that material producers and distributors that possess clear pricing power in addition to vertical integration are highly favored at present. On the other hand, experts urge investors to stay away from residential construction stocks since 2026 appears to be a poor year for the whole sector.

On April 6, S&P Global Ratings placed a B+ rating on Compass Inc. (NYSE:COMP) after the company’s takeover of Anywhere Real Estate Inc. This all-stock deal involves Compass assuming about $2.6 billion of Anywhere’s debt. The company also issued $1 billion in convertible notes for debt repayments and to cover integration expenses.

The merger makes Compass the top residential brokerage in the US, with an 18% market share and a much larger presence in all fifty states. The stable outlook for the stock is based on the expectation that Compass will achieve integration synergies, preserve its agent base, and bring its leverage down to under 5x in the next year.

Compass Inc. (NYSE:COMP) is a technology-led residential real estate brokerage firm. It operates mobile apps and online platforms such as CIRE and Compass to deliver services such as cloud-based CRM, marketing, client service, and title & settlement services. It also enables consumer-grade user interfaces, insightful dashboards, and reporting.

While we acknowledge the potential of COMP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than COMP and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.